Skip to main content

Recent News

renal.stone_.LBP_.jpg

ICYMI: Allopurinol Safety in CKD Patients

Jul 06, 2022

A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality.

Read Article
Axial Spondyloarthritis

ICYMI: Update on Axial SpA at EULAR 2022

Jul 05, 2022

This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.

Read Article
Watch: AURORA-2 Two-year Results Voclosporin For Lupus Nephritis https://t.co/UisuOOABxG#EULAR2022 https://t.co/Og8opUJO2h
Dr. John Cush @RheumNow (  View Tweet)
Jul 05, 2022
Voclosporin in lupus nephritis - good 3 year continuation data. #EULAR2022 abtr POS 0186 https://t.co/5EKmvIwTpV https://t.co/nh2bNkSp8G
Dr. John Cush @RheumNow (  View Tweet)
Jul 05, 2022
Baricitinib fails in 2 phase 3 lupus trials, BRAVE I & II #EULAR2022 abtr POS 0190 https://t.co/44e5NX4V1V
Dr. John Cush @RheumNow (  View Tweet)
Jul 05, 2022
Adults with JIA: It ain’t all child’s playhttps://t.co/z3xDjKH2ru https://t.co/9DDGYdpMSr
Dr. John Cush @RheumNow (  View Tweet)
Jul 05, 2022
New podcast up—“What Worries You, Masters You” We review recent news, regulatory and guideline updates from the past week. Studies on MTX use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.https://t.co/jRaLCQAt9K https://t.co/opa22JqU41
Dr. John Cush @RheumNow (  View Tweet)
Jul 04, 2022
Exercise and fibromyalgia? Metanalysis of 18 studies & 1184 pts, comparing aerobic, resistance & stretching. All 3 had large & significant effect on pain (not diff from each other); also improves QOL (possibly depression) https://t.co/RYba99OWCh https://t.co/izpHjeXWCt
Dr. John Cush @RheumNow (  View Tweet)
Jul 03, 2022
EMA has approved Secukinumab for the expanded approvals for use in pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) . Approvals based on the JUNIPERA trial, showing reduced the risk of flare & Dz activity w/ SEC https://t.co/6pWc6nEUd9 https://t.co/gGGyzEEh0u
Dr. John Cush @RheumNow (  View Tweet)
Jul 03, 2022
Inferior IL-17 Inhibitor Responses in Psoriatic Women Pooled data from two large (IXE trials show that male patients had greater clinical responses than did female patients with PsA are largely unexplored. Reasons for this is unexplained.https://t.co/OAu6gCweDt https://t.co/lsM6hZUwNQ
Dr. John Cush @RheumNow (  View Tweet)
Jul 03, 2022
Study of IV CTX (n 13) vs mepolizumab (n 7)(MPZ; IL-5 inhib) in severe eosinophilic granulomatosis polyangiitis. BVAS & EOS# equal at mo 1 & 6, but MPZ had better retention(61 vs 5%) & less AEs (29% vs 54%) https://t.co/7s38a67C1r https://t.co/oXLb1ctoc7
Dr. John Cush @RheumNow (  View Tweet)
Jul 03, 2022
New Updated GRAPPA Psoriatic Arthritis Recommendations The GRAPPA treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains." A great reference to print & carry.https://t.co/0K8LP3LA9j https://t.co/1fJlzPKLWl
Dr. John Cush @RheumNow (  View Tweet)
Jul 02, 2022
JAMA Clinical Review 15 min podcast on treatment of carpal tunnel syndrome and trigger finger and common hand problems in clinical practice; featuring Drs. Mary M. McDermott, and Kelly Currie https://t.co/IhD6iqVyqC https://t.co/aChPLIbuEu
Dr. John Cush @RheumNow (  View Tweet)
Jul 02, 2022
The EMA's CHMP has positively recommended upadacitinib for use in Non-radiographic axial spondyloarthritis (nr-axSpA) based on Phase 3 SELECT-AXIS 2 study showing superior ASAS40 responses at week 14 https://t.co/uc7oOKglLX https://t.co/yz7M8U3rkk
Dr. John Cush @RheumNow (  View Tweet)
Jul 02, 2022
JAMA Patient Page on "What is Carpal Tunnel Syndrome ? A great patient resource, full read with graphics https://t.co/lL9209YpdL https://t.co/28ceu2obma
Dr. John Cush @RheumNow (  View Tweet)
Jul 02, 2022
🆕🚨Possible future avenues for myositis therapeutics: DM,IMNM&IBM Current treatment options in IIM management 1st line:GC+ Skin➡️MTX/AZR/MMF Muscle➡️AZR/MMF/MTX Lung➡️AZR/MMF Dysphagia/Diaphragmatic weakness➡️IVIG RP-ILD➡️IVIG+CNI+CYC/RTX Calcinosis➡️JAKihttps://t.co/G3vN055Gyq https://t.co/Qy9MULgeMs
EnvisionRheumat @ERheumat (  View Tweet)
Jul 01, 2022
Idiopathic inflammatory myopathies, Camille Rasmussen #BJHM #MedEd #FOAMed #Medtwitter #Myopathy #rheumtwitter #MedStudentTwitter https://t.co/dsqwHIAqnX
Brown Journal of Hospital Medicine @BrownJHM (  View Tweet)
Jul 01, 2022
Are you an Expert in Still's disease, Periodic Fevers, FMF or Autoinflammatory Dz? We will add you to our expert referral listing. DM me to get on the list! https://t.co/hCkC1Yu9Nh
Dr. John Cush @RheumNow (  View Tweet)
Jul 01, 2022
Novel Anti-TNF Shines in Rheumatoid Arthritis Trial A new way of inhibiting tumor necrosis factor (TNF) for treating rheumatoid arthritis showed strong results in a phase II/III clinical trial, researchers said.https://t.co/fTmWeIrVD5 https://t.co/LPk2Ok2gac
Dr. John Cush @RheumNow (  View Tweet)
Jul 01, 2022
Placebo Works Best in Combination Analysis of two large clinical trial datasets shows that placebo response rates in randomised controlled trials (RCTs) of patients with rheumatoid arthritis are better when the patient continued background MTX.https://t.co/JmNGRQWv6L https://t.co/77LdcTwCvl
Dr. John Cush @RheumNow (  View Tweet)
Jul 01, 2022
×